David Milligan - Jun 16, 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Brian Lynch, as attorney-in-fact for David Milligan, M.D.
Stock symbol
MDGL
Transactions as of
Jun 16, 2022
Transactions value $
$0
Form type
4
Date filed
6/21/2022, 06:30 AM
Previous filing
Jun 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to buy) Award $0 +9.47K $0.00 9.47K Jun 16, 2022 Common Stock 9.47K $65.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.